Patents by Inventor Colin Mansfield

Colin Mansfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180311236
    Abstract: Disclosed is a mast cell inhibitor, a pharmaceutical composition and a method for the treatment of patients afflicted with Parkinson's disease, wherein the patients are treated with a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a compound selected from imatinib, cromolyn sodium, midostaurin, BLU-285, bosutinib, ibrutinib, LAS189386, DP-2618, fostamatinib, dasatinib, sunitinib, axitinib, pazopanib, and toceranib or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Application
    Filed: October 28, 2016
    Publication date: November 1, 2018
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Patent number: 10092564
    Abstract: Disclosed is a method for treating patients afflicted with non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS) whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) prior to treatment initiation is <1.1 points per month, the method including administering a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: October 9, 2018
    Assignee: AB SCIENCE
    Inventors: Alain Moussy, Jean-Pierre Kinet, Colin Mansfield
  • Publication number: 20180117037
    Abstract: Disclosed is a method for treating patients afflicted with non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS) whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) prior to treatment initiation is <1.1 points per month, the method including administering a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Application
    Filed: March 24, 2017
    Publication date: May 3, 2018
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20170340629
    Abstract: Disclosed is a method for treating breast cancer in a subject in need thereof, including administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with a therapeutically effective amount of a chemotherapeutic agent.
    Type: Application
    Filed: December 15, 2015
    Publication date: November 30, 2017
    Applicant: AB SCIENCE
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20170196853
    Abstract: A treatment of patients afflicted with prostate cancer, wherein the treatment includes administering to a mammal in need thereof at least one tyrosine kinase inhibitor or mast cell inhibitor that is an inhibitor of kinase activity selected from the tyrosine kinases of: c-Kit, PDGFR, LYN, FYN, or any combination thereof, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Application
    Filed: June 2, 2014
    Publication date: July 13, 2017
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20170119760
    Abstract: A mast cell inhibitor, a pharmaceutical composition and a method for treating patients afflicted with Progressive Supranuclear Palsy (PSP), wherein the patients are treated with a tyrosine kinase inhibitor, c-Kit inhibitor or mast cell inhibitor, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Application
    Filed: October 28, 2016
    Publication date: May 4, 2017
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20170020867
    Abstract: A method for treating patients afflicted with Crohn's disease, wherein the patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient for treatment of Crohn's disease.
    Type: Application
    Filed: July 21, 2016
    Publication date: January 26, 2017
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20160263110
    Abstract: A treatment of patients afflicted with Amyotrophic Lateral Sclerosis (ALS), wherein the patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient
    Type: Application
    Filed: November 4, 2014
    Publication date: September 15, 2016
    Inventors: Jean Pierre KINET, Alain MOUSSY, Colin MANSFIELD
  • Publication number: 20160175302
    Abstract: The present invention relates to a method for treating gastric cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor, in combination with a therapeutically effective amount of a chemotherapeutic agent.
    Type: Application
    Filed: December 17, 2015
    Publication date: June 23, 2016
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20150290235
    Abstract: A method for treating patients afflicted with cancer (including hematological malignancies) or viral infections, wherein the patients are under treatment or are to be treated with at least one anticancer or antiviral agent, and in particular (deoxy)nucleotide or (deoxy)nucleoside analog drugs, includes administering at least one small molecule inhibitor/activator (including ATP competitive inhibitors, signal transduction inhibitors/activators, protein kinase inhibitors/activators, and tyrosine kinase inhibitors/activators) in combination with the (deoxy) nucleotide or (deoxy)nucleoside analog, and wherein the small molecule inhibitor/activator is administered in sufficient amount to modulate deoxynucleotide or deoxynucleoside kinase activity (and in particular deoxycytidine kinase activity) to modulate activation of the (deoxy)nucleotide or (deoxy)nucleoside analog in vivo with a subsequent therapeutically beneficial anticancer or antiviral effect.
    Type: Application
    Filed: November 8, 2013
    Publication date: October 15, 2015
    Inventors: Laurent Gros, Patrice Dubreuil, Alain Moussy, Stephane Audebert, Colin Mansfield
  • Patent number: 7754490
    Abstract: A number of reagent-free infrared spectroscopic diagnostic and analytical methods have been established previously, making use of dry biofluid films. For example, this approach has successfully measured high concentration analytes of serum and urine. However, a number of low concentration diagnostically relevant analytes presently elude detection by infrared spectroscopy. This is due in part to their relatively low concentration and in part to spectral interference by other strongly absorbing constituents. The applicability of the technique would be broadened substantially if it were possible to separate and concentrate, lower concentration analytes, e.g. serum creatinine and urine proteins, from the obscuring presence of relatively high concentration compounds. The invention disclosed achieves this is through microfluidic sample preconditioning based upon laminar fluid diffusion interfaces.
    Type: Grant
    Filed: May 5, 2005
    Date of Patent: July 13, 2010
    Inventors: Colin Mansfield, Anthony Shaw
  • Publication number: 20070215809
    Abstract: A number of reagent-free infrared spectroscopic diagnostic and analytical methods have been established previously, making use of dry biofluid films. For example, this approach has successfully measured high concentration analytes of serum and urine. However, a number of low concentration diagnostically relevant analytes presently elude detection by infrared spectroscopy. This is due in part to their relatively low concentration and in part to spectral interference by other strongly absorbing constituents. The applicability of the technique would be broadened substantially if it were possible to separate and concentrate, lower concentration analytes, e.g. serum creatinine and urine proteins, from the obscuring presence of relatively high concentration compounds. The invention disclosed achieves this is through microfluidic sample preconditioning based upon laminar fluid diffusion interfaces.
    Type: Application
    Filed: May 5, 2005
    Publication date: September 20, 2007
    Inventors: Colin Mansfield, Anthony Shaw